Media Articles Related to Xifaxan (Rifaximin)
FDA approves two therapies to treat IBS-D
Source: Irritable-Bowel Syndrome News From Medical News Today [2015.05.28]
The U.S. Food and Drug Administration has approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with...
Salix's TARGET 3 study examines the safety and efficacy of repeat treatment with Rifaximin for IBS with diarrhea
Source: Irritable-Bowel Syndrome News From Medical News Today [2014.10.23]
Salix Pharmaceuticals, Ltd. has announced that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center will present the results of TARGET 3 in a late-breaking podium presentation at the American...
Published Studies Related to Xifaxan (Rifaximin)
Safety and tolerability of rifaximin for the treatment of irritable bowel
syndrome without constipation: a pooled analysis of randomised, double-blind,
placebo-controlled trials. 
events (AEs) in phase 2b and phase 3 non-C IBS trials... CONCLUSIONS: The safety and tolerability profile of rifaximin during treatment
[Role of rifaximin in the treatment of colonic diverticular disease]. [Article in Italian] 
Diverticular disease of the colon is the fifth most important gastrointestinal
disease in terms of direct and indirect healthcare costs in western countries. Although most patients with colonic diverticula remain asymptomatic for their
whole life, in 20-25% of cases will develop symptoms.No definitive conclusion can be drawn regard a possible role
of rifaximin for preventing diverticulitis.
Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. [2011.10]
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is one cause of a poor response to a gluten-free diet (GFD) and persistent symptoms in celiac disease. Rifaximin has been reported to improve symptoms in non-controlled trials. AIMS: To determine the effect of rifaximin on gastrointestinal symptoms and lactulose-hydrogen breath tests in patients with poorly responsive celiac disease... CONCLUSIONS: Rifaximin does not improve patients' reporting of gastrointestinal symptoms and hydrogen breath tests do not reliably identify who will respond to antibiotic therapy.
Rifaximin: new therapeutic indication and future directions. [2011.07]
BACKGROUND: Rifaximin is a nonabsorbable oral antibiotic that acts locally in the gastrointestinal tract with minimal systemic adverse effects. Rifaximin received new labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease in March of 2010. OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, and pharmacodynamics of rifaximin. The efficacy and safety of rifaximin in reducing the risk of the recurrence of overt HE in patients with advanced liver disease, the new US Food and Drug Administration-approved indication, is the focus of this review. Emerging data on the use of rifaximin in irritable bowel syndrome (IBS) and Clostridium difficile infection (CDI) are also evaluated... CONCLUSIONS: Rifaximin can be an effective option for reduction in the risk of the recurrence of HE in patients with advanced liver disease. Studies suggest that rifaximin provides relief of global symptoms of diarrhea-predominant IBS and bloating. Use of rifaximin in CDI requires further study. Copyright (c) 2011 Elsevier HS Journals, Inc. All rights reserved.
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011.06]
The aim of this study was to evaluate the efficacy of levofloxacin and rifaximin based quadruple regimen as first-line treatment for Helicobacter pylori infection. A prospectively randomized, double-blinded, parallel group, comparative study was performed...
Clinical Trials Related to Xifaxan (Rifaximin)
Rifaximin Treatment of Papulopustular Rosacea [Not yet recruiting]
The purpose of this study is to determine the effects of rifaximin on skin symptoms in
patients with rosacea by double-blinded, placebo-controlled, crossover study.
A Pilot Study of Xifaxan to Treat Patients With PSC [Recruiting]
In the current protocol, we propose the assessment of potential beneficial effects of the
antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15
adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice
daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or
equal to 40 kg will receive Xifaxan, 550 mg twice daily.
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer [Recruiting]
The most common long-term problems after rectal surgery are bowel problems. These problems
can include needing to pass bowel movements a lot, loose or mushy stools, inability to fully
clear your bowels, and/or poor control of gas and stool. The investigators believe that a
major cause of these problems is too much bacteria in the bowel and treatment with
antibiotic tablets will hopefully help improve these bowel problems. In order to test this
idea, the Colorectal Surgery Service of Memorial Sloan Kettering Cancer Center is sponsoring
a clinical trial. This trial will compare the antibiotic rifaximin and a placebo (a harmless
tablet that has no effect) in the treatment of these bowel problems. Rifaximin is a well
established drug that has minimal side effects.
Study of Rifaximin in Minimal Hepatic Encephalopathy [Recruiting]
Rifaximin therapy will improve brain functioning on MRI scanning.
Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) [Recruiting]
Acute graft versus host disease is a frequent and often life threatening complication of
allogeneic blood and marrow transplantation. The bacteria that normally reside in the
intestine play a critical role in its development. Injury to the lining of the bowel that
results from the high dose chemotherapy or radiation that transplant patients receive during
the week preceding the transplant allows the bacteria to invade the intestines and spread to
nearby lymph nodes. This, in turn, causes inflammation which has been shown to promote
GVHD. Both pre-clinical and clinical research has demonstrated that oral antibiotics can
prevent graft versus host disease by inhibiting these gut bacteria. Rifaximin has several
features that suggest it could be effective in preventing GVHD. Rifaximin prophylaxis might
also provide an added benefit by protecting highly immunocompromised transplant patients
from severe bacterial infections. This pilot trial will allow the investigators to determine
the feasibility of using Rifaximin for prevention of GVHD and infection in patients
undergoing allogeneic blood and marrow transplantation. The preliminary results will be
used to plan a more definitive trial.
Reports of Suspected Xifaxan (Rifaximin) Side Effects
Renal Failure (5),
Colitis Ischaemic (3),
Staphylococcal Infection (3),
Enterococcal Infection (2),
Hepatic Failure (2),
Bacterial Prostatitis (2),
Oedema Peripheral (2), more >>